Skip to content
lifestyle.nextmentors.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
argenx SE
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
October 8, 2026
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren’s Disease
October 8, 2026
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
September 29, 2026
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
September 17, 2026
argenx Completes Acquisition of Forte Biosciences, Inc.
August 27, 2026
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
August 17, 2026
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
August 6, 2026
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
August 3, 2026
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
July 27, 2026
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
July 23, 2026
1
2
Next Page
→